课题基金 / 基金详情

Malaria Vaccine: Pfs230

Malaria Vaccine: Pfs230
疟疾疫苗：Pfs230
批准号：
8745458
负责人：
Patrick Duffy
金额：
$168.11万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/8745458
关键词：
AnimalsAntibodiesAreaBiological AssayComplementCyclic GMPDataEscherichia coliGermGoalsHumanImmune SeraMalariaMalaria VaccinesMembraneParasitesPichiaPopulationProductionProteinsRecombinantsSurfaceVaccinesWheatbaseburden of illnessexpression cloningfeedingsuccesstransmission processvaccine evaluation

项目摘要

项目成果

Patrick Duffy的其他基金

相似基金

相关文献

中文摘要
翻译
在成功评估小麦胚表达Pfs 230结构域的基础上，重组Pfs 230结构域也在巴斯德毕赤酵母和E.杆菌 针对这些结构域产生的抗血清在离体标准膜饲养测定中以补体依赖性方式表现出有效的传递阻断活性。 评价多个表达克隆的重组Pfs 230产率和功能性抗体的诱导。 选择毕赤酵母表达克隆，并制备cGMP级重组Pfs 230。 目前的努力集中在产生cGMP级Pfs 230-EPA，与Pfs 25-EPA疫苗组合并在人体中测试为潜在有效的传播阻断疫苗。
英文摘要
Built on success in evaluating the wheat germ-expressed Pfs230 domains, recombinant Pfs230 domains were also expressed in P. pastoris and E. coli. Antisera raised against these domains demonstrated potent transmission blocking activities in an ex vivo standard membrane feeding assay, in a complement-dependent manner. Multiple expression clones were evaluated for their recombinant Pfs230 production yield and induction of functional antibodies. A Pichia expression clone was selected, and cGMP grade recombinant Pfs230 was manufactured. The current efforts are focused on generating cGMP grade Pfs230-EPA, to be combined with Pfs25-EPA vaccine and tested in humans as potentially effective transmission blocking vaccine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Malaria Surveillance and Research Studies in Liberia and Guinea-Conakry
Malaria Transmission Blocking Vaccine Discovery
Malaria Pathogenesis in young children and vaccine discovery
Malaria Vaccine: Pfs25-rEPA
海外基金